Marina DÃ-az-BeyÃ¡

List of Publications by Year
in descending order

41 papers	1,097 citations	567281 15 h-index	454955 30 g-index
43 all docs	43 docs citations	43 times ranked	2061 citing authors

#	Article	IF	Citations
1	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances, 2022, 6, 1193-1206.	5.2	26
2	Results of <scp>ARI</scp>â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp>â€positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	4.1	6
3	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	8.2	80
4	Outcomes and prognostic factors of adults with refractory or relapsed Tâ€cell acute lymphoblastic leukemia included in measurable residual diseaseâ€oriented trials. Hematological Oncology, 2021, 39, 529-538.	1.7	3
5	Adverse prognostic impact of complex karyotype (â‰¥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.8	11
6	Clinic and therapeutic potential of non-coding RNAs in cancer. Translational Cancer Research, 2021, 10, 0-0.	1.0	0
7	Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	1.4	0
8	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. Blood, 2021, 138, 3486-3486.	1.4	2
9	Factors associated with the clinical outcome of patients with relapsed/refractory CD19⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
10	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. Haematologica, 2020, 105, e294-e297.	3.5	29
11	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. British Journal of Haematology, 2020, 191, 52-61.	2.5	28
12	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEKâ€NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 2020, 189, 920-925.	2.5	16
13	A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories. Blood, 2020, 136, 9-10.	1.4	1
14	Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1Ã— 109/L Should be Classified As CMML. Blood, 2020, 136, 10-11.	1.4	0
15	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). Blood, 2020, 136, 32-33.	1.4	0
16	Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). Blood, 2020, 136, 31-32.	1.4	0
17	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. Blood, 2020, 136, 13-14.	1.4	0
18	Emergence ofNPM1Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia withNPM1Mutation: Proposed Mechanisms of Clonal Evolution. Blood, 2020, 136, 39-40.	1.4	0

#	Article	IF	Citations
19	Early Tâ€cell precursor lymphoblastic leukaemia: response to <scp>FLAG</scp>â€<scp>IDA</scp> and highâ€dose cytarabine with sorafenib after initial refractoriness. British Journal of Haematology, 2019, 185, 755-757.	2.5	5
20	Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry. Blood, 2019, 134, 1321-1321.	1.4	0
21	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2394-2404.	1.3	16
22	Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. Leukemia and Lymphoma, 2018, 59, 2383-2393.	1.3	1
23	A phase Iâ€“II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Annals of Hematology, 2018, 97, 763-772.	1.8	39
24	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS ONE, 2018, 13, e0199531.	2.5	60
25	Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols. Blood, 2018, 132, 1553-1553.	1.4	6
26	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). Blood, 2018, 132, 1385-1385.	1.4	1
27	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell International, 2015, 15, 122.	4.1	4
28	The lincRNAHOTAIRM1, located in theHOXAgenomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget, 2015, 6, 31613-31627.	1.8	78
29	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. Annals of Hematology, 2014, 93, 1695-1703.	1.8	25
30	Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5. Blood, 2014, 124, 134-134.	1.4	4
31	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	1.4	2
32	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood, 2014, 124, 1003-1003.	1.4	0
33	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. Acta Haematologica, 2013, 129, 65-71.	1.4	3
34	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 2013, 121, 2734-2738.	1.4	246
35	MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients. PLoS ONE, 2013, 8, e64716.	2.5	21
36	Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma. Blood, 2013, 122, 1422-1422.	1.4	0

#	Article	IF	Citations
37	The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade. Biology of Blood and Marrow Transplantation, 2011, 17, 1713-1720.	2.0	170
38	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia Research, 2011, 35, 1276-1278.	0.8	4
39	The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. Blood, 2010, 116, 6147-6148.	1.4	41
40	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Annals of Hematology, 2010, 89, 1233-1237.	1.8	134
41	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	2.4	1